The Medical Letter on Drugs and Therapeutics
Milnacipran (Savella) for Fibromyalgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 7/8/09: Milnacipran article: In the 2nd sentence, “similar to gabapentin” was added. It now reads, “...a gamma-aminobutyric acid (GABA) analog similar to gabapentin...”

Milnacipran (Savella – Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gamma-aminobutyric acid (GABA) analog similar to gabapentin also approved for treatment of diabetic neuropathy, post-herpetic neuralgia and epilepsy,1 and duloxetine, an SNRI also approved for treatment of depression, diabetic neuropathy and generalized anxiety disorder.2

FIBROMYALGIA — Fibromyalgia is characterized by chronic musculoskeletal pain, tenderness, fatigue and sleep disturbance. Genetic, environmental and psychosocial factors appear to influence its expression.3-5

In addition to the FDA-approved drugs, medications used to treat fibromyalgia have included analgesics, muscle relaxants, anticonvulsants, and antidepressants ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Milnacipran (Savella) for Fibromyalgia
Article code: 1314b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian